Unichem Labs bags USFDA nod for hypertension drug Doxazosin

The product will be commercialized from Unichem's Goa Plant.

Written By :  Ruchika Sharma
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-01-11 08:57 GMT   |   Update On 2024-03-26 10:55 GMT
Advertisement

Mumbai: Unichem Laboratories Limited has announced that the Company has received Abbreviated New Drug Application (ANDA) approval for its Doxazosin Tablets USP, 1 mg, 2 mg, 4 mg and 8 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Cardura (Doxazosin) Tablets, 1 mg, 2 mg, 4 mg and 8 mg, of Viatris Specialty, LLC.

Doxazosin tablets are indicated for the treatment of hypertension, to lower blood pressure. 

According to the World Health Organisation (WHO), Hypertension (high blood pressure) is when the pressure in your blood vessels is too high (140/90 mmHg or higher). It is common but can be serious if not treated. 

The product will be commercialized from Unichem’s Goa Plant.

Read also: USFDA nod to Unichem Labs Prasugrel Tablets to reduce thrombotic CV events rate in acute coronary syndrome

Medical Dialogues team had earlier reported that Unichem Labs had received ANDA approval for its Labetalol Hydrochloride Tablets, USP 100 mg, 200 mg, and 300 mg from the USFDA.

Read also: Unichem Labs bags USFDA nod for Labetalol Hydrochloride Tablets

Headquartered in Mumbai, Unichem Laboratories Limited is an international, integrated, specialty pharmaceutical company. The company was founded in 1944 by Padmabhushan Late Mr. Amrut V Mody. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in several markets across the world.
Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News